1
`
`EX2027
`Eli Lilly & Co. v. Teva Pharms. Int'l GMBH
`IPR2018-01426
`
`

`

`US 9,266,951 B2
`
`Page 2
`
`(56)
`
`References Cited
`
`U.S. PATENT DOCUMENTS
`
`8,586,045
`8,597,649
`8,623,366
`8,734,802
`9,115,194
`2002/0162125
`2003/0194404
`2004/0110170
`2005/0234054
`2006/0183700
`2009/0220489
`2010/0172895
`2011/0054150
`2011/0257371
`2011/0305711
`2012/0009192
`2012/0225075
`2012/0294797
`2012/0294802
`2013/0216535
`2013/0295087
`2013/0295088
`2014/0147438
`2014/0308290
`2014/0314767
`2015/0050267
`2015/0266948
`2015/0291690
`2015/0307607
`2015/0322142
`2015/0361172
`2015/0361173
`
`B2
`B2
`B2
`B1
`B2
`A1
`A1
`A1
`A1
`A1
`A1
`A1
`A1
`A1
`A1
`A1
`A1
`A1
`A1
`A1
`A1
`A1
`A1
`A1
`A1
`A1
`A1
`A1
`A1
`A1
`A1
`A1
`
`11/2013
`12/2013
`1/2014
`5/2014
`8/2015
`10/2002
`10/2003
`6/2004
`10/2005
`8/2006
`9/2009
`7/2010
`3/2011
`10/2011
`12/2011
`1/2012
`9/2012
`11/2012
`11/2012
`8/2013
`11/2013
`11/2013
`5/2014
`10/2014
`10/2014
`2/2015
`9/2015
`10/2015
`10/2015
`11/2015
`12/2015
`12/2015
`
`Zeller et a1.
`Zeller et a1.
`Pios et a1.
`Zeller et a1.
`Zeller et a1.
`Salmon et a1.
`Greenfeder et a1.
`Pisegna et al.
`Mueller et a1.
`Vater et a1.
`Zeller et a1.
`Boone et al.
`Poulsen et a1.
`Poulsen et a1.
`Allan et al.
`Zeller et a1.
`Pios et a1.
`Kovacevich et a1.
`Russo et a1.
`Zeller et a1.
`Poulsen et a1.
`Poulsen et a1.
`Zeller et a1.
`Pios et a1.
`Pios et a1.
`Zeller et a1.
`Bigal et al.
`Zeller et a1.
`Poulsen et a1.
`Bigal et al.
`Zeller et a1.
`Zeller et a1.
`
`FOREIGN PATENT DOCUMENTS
`
`EP
`EP
`EP
`EP
`JP
`JP
`JP
`JP
`RU
`WO
`W0
`WO
`WO
`W0
`W0
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`
`0212432 A2
`1031350 A1
`1770091 A1
`2380592 A2
`H 07196700 A
`H08268874 A
`2007523870 A
`2009515942 A
`2329062 C2
`WO91/00737 A1
`WO 94/21665 A1
`WO-9604928 A1
`WO-9709046 A1
`WO 97/41223 A1
`WO 98/03534 A1
`WO-9809630 A1
`WO-9811128 A1
`WO-9856779 A1
`WO-9958572 A1
`WO-0018764 A1
`WO-03093472 A2
`WO-03104236 A1
`WO-2004003019
`A2
`WO-2004014351
`A2
`WO-03093472
`A3
`WO-2004050683
`A2
`WO-2004003019
`A3
`WO-2004082602
`A2
`WO-2004082605
`A2
`WO-2004082678
`A 1
`WO-2004083187
`A 1
`WO-2004087649
`A2
`WO-2004091514
`A2
`WO-2004092166
`A2
`WO-2004092168
`A 1
`WO-2005009962
`A 1
`WO-2005100360
`A 1
`WO-2006077212
`A 1
`A2
`WO 2007/025286
`
`3/1987
`8/2000
`4/2007
`10/2011
`8/1995
`10/1996
`8/2007
`4/2009
`7/2008
`1/1991
`9/1994
`2/1996
`3/1997
`11/1997
`1/1998
`3/1998
`3/1998
`12/1998
`11/1999
`4/2000
`11/2003
`12/2003
`1/2004
`2/2004
`3/2004
`6/2004
`9/2004
`9/2004
`9/2004
`9/2004
`9/2004
`10/2004
`10/2004
`10/2004
`10/2004
`2/2005
`10/2005
`7/2006
`3/2007
`
`W0
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`W0
`WO
`
`WO 2007/035906 A2
`WO-2007025212 A2
`WO-2007054809 A2
`WO-2007061676 A2
`WO-2007076336 A1
`WO-2007054809 A3
`WO-2007025212 A3
`WO-2007061676 A3
`WO-2008011190 A1
`WO 2010/006168 A2
`WO-2011024113 A1
`
`3/2007
`3/2007
`5/2007
`5/2007
`7/2007
`8/2007
`12/2007
`12/2007
`1/2008
`1/2010
`3/2011
`
`OTHER PUBLICATIONS
`Amara, et a1. Expression in brain of a messenger RNA encoding a
`novel neuropeptide homologous to calcitonin gene-related peptide.
`Science. Sep. 13, 1985;229(4718):1094-7.
`Ambalavanar,
`et
`a1. Deep tissue
`inflammation upregulates
`neuropeptides and evokes nociceptive behaviors which are modu-
`lated by a neuropeptide antagonist. Pain. Jan. 2006;120(1-2):53-68.
`Epub Dec. 13, 2005.
`American Academy of Neurology. New Drugs Offer Hope for
`Migraine Prevention. Apr. 22, 2014.
`American Headache Society. Initial Results for LY2951742, a New
`Investigational Medicine for Migraine Prevention. 2014. Available at
`http ://www. americanheadachesociety. org/initialiresultsifori
`1y295 1742iainewiinvestigationalimedicineiforimigraine,
`prevention. Accessed May 15, 2014.
`An. Therapeutic Monoclonal Antibodies From Bench to Clinic,
`Wiley Chapter 31, pp. 711-762. 2009.
`Andrew, et a1. Monoclonal antibodies distinguishing alpha and beta
`forms of calcitonin gene-related peptide. J Immunol Methods. Nov.
`6, 1990;134(1):87-94.
`Armour, et a1. Recombinant human IgG molecules lacking chamma
`receptor I binding and monocyte triggering activities. Eur J Immunol.
`Aug. 1999;29(8):2613-24.
`Arulmani, et al. Calcitonin gene-related peptide and its role in
`migraine pathophysiology. Eur J Pharmacol. Oct. 1, 2004;500(1-
`3):3 15 -30.
`Arulmozhi, et a1. Migraine: current concepts and emerging therapies.
`Vascul Pharmacol. Sep. 2005;43(3):176-87.
`Ashina, et al. Evidence for increased plasma levels of calcitonin
`gene-related peptide in migraine outside of attacks. Pain. May
`2000;86(1-2):133-8.
`ATCC website search for PTA-6866 deposit (p. 1; Oct. 22, 2010).
`ATCC website search for PTA-6867 deposit (p. 1; Oct. 22, 2010).
`Aziz. Visceral hypersensitivity: fact or fiction. Gastroenterology.
`Aug. 2006;131(2):661-4.
`Balint, et a1. Antibody engineering by parsimonious mutagenesis.
`Gene. Dec. 27, 1993;137(1):109-18.
`Bard, et a1. Peripherally administered antibodies against amyloid
`beta-peptide enter the central nervous system and reduce pathology
`in a mouse model of Alzheimer disease. Nat Med. Aug.
`2000;6(8):916-9.
`Bennett, et a1. Alleviation of mechanical and thermal allodynia by
`CGRP(8-37) in a rodent model of chronic central pain. Pain. May
`2000;86(1-2):163-75.
`Benschop; et al., “Development of a novel antibody to calcitonin
`gene-related peptide for the treatment of osteoarthritis-related pain.
`Osteoarthritis Cartilage. Apr. 2014;22(4):578-85. doi: 10.1016/j.
`joca.2014.01.009. Epub Feb. 6, 2014.”
`Bigal; et al., “Safety and tolerability of LBR-101, a humanized
`monoclonal antibody that blocks the binding of CGRP to its receptor:
`Results of
`the Phase
`1
`program. Cephalalgia. Dec.
`23,
`2013;34(7):483-492.”
`Bigal; et al., “Cardiovascular and hemodynamic parameters in
`women following prolonged CGRP inhibition using LBR-101, a
`monoclonal
`antibody
`against
`CGRP.
`Cephalalgia.
`Oct.
`2014;34(12):968-76. doi: 10.1177/0333102414527646. Epubl Mar.
`24, 2014.”
`Bird, et a1. Single-chain antigen-binding proteins. Science. Oct. 21,
`1988;242(4877):423-6.
`Boerner, et a1. Production of antigen-specific human monoclonal
`antibodies from in vitro-primed human splenocytes. J Immunol. Jul.
`1,1991;147(1):86-95.
`
`2
`
`

`

`US 9,266,951 B2
`
`Page 3
`
`(56)
`
`References Cited
`OTHER PUBLICATIONS
`
`Brain, et al. Vascular actions of calcitonin gene-related peptide and
`adrenomedullin. Physiol Rev. Jul. 2004;84(3):903-34.
`Brorson, et al. Mutational analysis of avidity and fine specificity of
`anti-levan antibodies. J Immunol. Dec. 15, 1999;163(12):6694-701.
`Brummell, et al. Probing the combining site of an anti-carbohydrate
`antibody by saturation-mutagenesis: role of the heavy-chain CDR3
`residues. Biochemistry. Feb. 2, 1993;32(4):1180-7.
`Buckley, et al. The partial inhibition of inflammatory responses
`induced by capsaicin using the Fab fragment of a selective calcitonin
`gene-related peptide antiserum in rabbit skin. Neuroscience. Jun.
`1992;48(4):963-8.
`Burks, et al. In vitro scanning saturation mutagenesis of an antibody
`binding pocket. Proc Natl Aced Sci U S A. Jan. 21, 1997;94(2):412-7.
`Capel,
`et
`al. Heterogeneity of human IgG Fc
`receptors.
`Immunomethods. Feb. 1994;4(1):25-34.
`Caraceni, et al. Pain measurement tools and methods in clinical
`research in palliative care: recommendations of an Expert Working
`Group of the European Association of Palliative Care. J Pain Symp-
`tom Manage. Mar. 2002;23(3):239-55.
`Casset, et al. A peptide mimetic of an anti-CD4 monoclonal antibody
`by rational design. Biochem Biophys Res Commun.
`Jul. 18,
`2003;307(1):198-205.
`Cervero, et al.Visceral pain. Lancet. Jun. 19, 1999;353(9170):2145-
`8.
`Chen, et al. Selection and analysis of an optimized anti-VEGF anti-
`body: crystal structure of an affinity-matured Fab in complex with
`antigen. J Mol Biol. Nov. 5, 1999;293(4):865-81.
`Chothia, et al. Conformations of immunoglobulin hypervariable
`regions. Nature. Dec. 21-28, 1989;342(6252):877-83.
`Clynes, et al. Fc receptors are required in passive and active immunity
`to melanoma. Proc Natl Acad Sci U S A. Jan. 20, 1998;95(2):652-6.
`Cole et al. The EBV—hybridoma technique and its application to
`human lung cancer. In, Monoclonal Antibodies and Cancer Therapy
`(vol. 27, UCLA Symposia on Molecular and Cellular Biology, New
`Series) (eds. R.A. Reisfeld and S.Sell), NewYork: Alan R. Liss, Inc.;
`1985:77-96.
`Colman. Effects of amino acid sequence changes on antibody-anti-
`gen interactions. Res Immunol. Jan. 1994;145(1):33-6.
`Conner, et al. Interaction of calcitonin-gene-related peptide with its
`receptors. Biochem Soc Trans. Aug. 2002;30(4):451-5.
`Co-pending U.S. Appl. No. 13/621,981, filed Sep. 18,2012.
`Co-pending U.S. Appl. No. 13/623,206, filed Sep. 20, 2012.
`Co-pending U.S. Appl. No. 13/835,394, filed Mar. 25, 2013.
`Co-pending U.S. Appl. No. 14/612,110, filed Feb. 2, 2015.
`Co-pending U.S. Appl. No. 14/612,117, filed Feb. 2, 2015.
`Co-pending U.S. Appl. No. 14/664,715, filed Mar. 20, 2015.
`Co-pending U.S. Appl. No. 14/711,705, filed May 13, 2015.
`Co-pending U.S. Appl. No. 14/719,015, filed May 21,2015.
`Co-pending U.S. Appl. No. 14/841,440, filed Aug. 31, 2015.
`Co-pending U.S. Appl. No. 14/841,479, filed Aug. 31, 2015.
`Covell, et al. Pharmacokinetics of monoclonal immunoglobulin G1,
`F(ab‘)2, and Fab' in mice. Cancer Res. Aug. 1986;46(8):3969-78.
`Davies, et al. Affinity improvement of single antibody VH domains:
`residues in all three hypervariable regions affect antigen binding.
`Immunotechnology. Sep. 1996;2(3):169-79.
`De Haas, et al. Fc gamma receptors of phagocytes. J Lab Clin Med.
`Oct. 1995;126(4):330-41.
`De Pascalis, et al. Grafting of “abbreviated” complementarity-deter-
`mining regions containing specificity-determining residues essential
`for ligand contact
`to engineer a less immunogenic humanized
`monoclonal antibody. J Immunol. Sep. 15, 2002;169(6):3076-84.
`Declaration of Dr. Jes Olesen. Re: EP1957106. Jul. 11,2014.
`Declaration of Dr. Leonard Presta. Re: EP1957106. Jul. 11, 2014.
`Declaration of Dr. Robert Benschop. Re: EP1957106. Jul. 16, 2014.
`Delafoy, et al. Interactive involvement of brain derived neurotrophic
`factor, nerve growth factor, and calcitonin gene related peptide in
`colonic hypersensitivity in the rat. Gut. Jul. 2006;55(7):940-5. Epub
`Jan. 9, 2006.
`
`Dockray, et al. Immunoneutralization studies with calcitonin gene-
`related peptide. Ann NY Acad Sci. Jun. 30, 1992;657:258-67.
`Dodick; et al., “Safety and efficacy of ALD403, an antibody to
`calcitonin gene-related peptide, for the prevention of frequent epi-
`sodic migraine: a randomised, double-blind, placebo-controlled,
`exploratory phase 2 trial. Lancet Neurol. Nov. 2014;13(11):1100-7.
`doi: 10.1016/Sl474-4422(14)70209-1. Epub Oct. 5, 2014.”
`Dodick; et al., “Safety and efficacy of LY2951742, a monoclonal
`antibody to calcitonin gene-related peptide, for the prevention of
`migraine: a phase 2, randomised, double-blind, placebo-controlled
`study. Lancet Neurol. Sep. 2014;13(9):885-92. doi: 10.1016/Sl474-
`4422(14)70128-0. Epub Aug. 10, 2014.”
`Dodick; et al., “Authors’ reply re Site of effect of LY2951742 for
`migraine prophylaxis. Www.thelancet.com/neueology. vol. 14, Jan.
`2015; 32-33.”
`Doods, et al. Pharmacological profile of BIBN4096BS, the first
`selective small molecule CGRP antagonist. Br J Pharmacol. Feb.
`2000;129(3):420-3.
`Dufner, et al. Harnessing phage and ribosome display for antibody
`optimisation. Trends Biotechnol. Nov. 2006;24(11):523-9. Epub
`Sep. 26, 2006.
`Durham, et al. CGRP-receptor antagonistsia fresh approach to
`migraine therapy? N Engl J Med. Mar. 11, 2004;350(11):1073-5.
`Edvinsson, et al. Inhibitory effect of BIBN4096BS, CGRP(8-37), a
`CGRP antibody and an RNA-Spiegelmer on CGRP induced
`vasodilatation in the perfused and non-perfused rat middle cerebral
`artery. Br J Pharmacol. Mar. 2007;150(5):633-40. Epub Jan. 22,
`2007.
`Elshourbagy, et al. Molecular cloning and characterization of the
`porcine calcitonin gene-related peptide receptor. Endocrinology.
`Apr. 1998;139(4):1678-83.
`Escott, et al. Trigeminal ganglion stimulation increases facial skin
`blood flow in the rat: a major role for calcitonin gene-related peptide.
`Brain Res. Jan. 9, 1995;669(1):93-9.
`European office action dated Dec. 16, 2013 for EP Application No.
`10754584.
`European search report dated May 8, 2012 for EP Application No.
`1 1 166787 .9.
`Felson, et al. The American College of Rheumatology preliminary
`core set of disease activity measures for rheumatoid arthritis clinical
`trials. The Committee on Outcome Measures in Rheumatoid Arthritis
`Clinical Trials. Arthritis Rheum. Jun. 1993;36(6):729-40.
`Francis, et al. The irritable bowel severity scoring system: a simple
`method of monitoring irritable bowel syndrome and its progress.
`Aliment Pharmacol Ther. Apr. 1997;11(2):395-402.
`Fries, et al. The dimensions of health outcomes: the health assess-
`ment questionnaire, disability and pain scales. J Rheumatol. Sep.-
`Oct. 1982;9(5):789-93.
`Frobert, et al. A sensitive sandwich enzyme immunoassay for
`calcitonin gene-related peptide (CGRP): characterization and appli-
`cation. Peptides. 1999;20(2):275-84.
`Gallai, et al. Vasoactive peptide levels in the plasma of young
`migraine patients with and without aura assessed both interictally and
`ictally. Cephalalgia. Oct. 1995;15(5):384-90.
`from
`protects
`Gay,
`et
`al.
`Interleukin-6
`genetic
`ablation
`trinitrobenzene sulfonic acid-induced colitis in mice. Putative effect
`of
`antiinflammatory
`cytokines.
`Neuroimmunomodulation.
`2006;13(2):114-21. Epub Oct. 14, 2006.
`Goadsby, et al. Migrainegcurrent understanding and treatment. N
`Engl J Med. Jan. 24, 2002;346(4):257-70.
`Goadsby, et al. Vasoactive peptide release in the extracerebral circu-
`lation of humans during migraine headache. Ann Neurol. Aug.
`1990;28(2):183-7.
`Grennan, et al. Textbook of Pain. 1994, pp. 397-407.
`Guyer, et al. Immunoglobulin binding by mouse intestinal epithelial
`cell receptors. J Immunol. Aug. 1976;117(2):587-93.
`Hakala, et al. Modelling constrained calcitonin gene-related peptide
`analogues. Protein Eng. Feb. 1996;9(2):143-8.
`treatment of
`Hogue,
`et
`al. Pathophysiology and first-line
`osteoarthritis. Ann Pharmacother. Apr. 2002;36(4):679-86.
`Holm, et al. Functional mapping and single chain construction ofthe
`anti-cytokeratin 8 monoclonal antibody TSl. Mol Immunol. Feb.
`2007;44(6):1075-84. Epub Sep. 20, 2006.
`
`3
`
`

`

`US 9,266,951 B2
`
`Page 4
`
`(56)
`
`References Cited
`OTHER PUBLICATIONS
`
`therapy. Trends
`
`Holman, et al. Human alpha- and beta-CGRP and rat alpha-CGRP are
`coronary vasodilators in the rat. Peptides. Mar.-Apr. 1986;7(2):231-
`5.
`Holt, et al. Domain antibodies: proteins for
`Biotechnol. Nov. 2003;21(11):484-90.
`Hoogenboom, et al. By-passing immunisation. Human antibodies
`from synthetic repertoires of germline VH gene segments rearranged
`in vitro. J Mol Biol. Sep. 20, 1992;227(2):381-8.
`Huston, et al. Protein engineering of antibody binding sites: recovery
`of specific activity in an anti-digoxin single-chain Fv analogue pro-
`duced in Escherichia coli. Proc Natl Acad Sci U S A. Aug.
`1988;85(16):5879-83.
`“Silberstein. Emerging target-based paradigms to prevent and treat
`migraine. Clin Pharmacol Ther. Jan. 2013;93(1):78-85. doi: 10.1038/
`clpt.2012.198. Epub Dec. 5, 2012.”
`International search report and written opinion dated May 9, 2007 for
`PCT/IB2006/003181.
`International search report and written opinion dated Jul. 29, 2009 for
`PCT/IB2009/050852.
`International search report and written opinion dated Jul. 31, 2009 for
`PCT/IB2009/050849.
`International search report and written opinion dated Nov. 11, 2010
`for PCT/IB2010/053787.
`“International search report and written opinion dated Jul. 8, 2015 for
`PCT/US2015/021887.”
`Janeway and Travers. Immunobiology; Garland Publishing. p. G-2
`(1994).
`Jang, et al. The structural basis for DNA binding by an anti-DNA
`autoantibody. Mol Immunol. Dec. 1998;35(18):1207-17.
`Juhasz, et al. NO-induced migraine attack: strong increase in plasma
`calcitonin gene-related peptide (CGRP) concentration and negative
`correlation with
`platelet
`serotonin
`release.
`Pain Dec.
`2003;106(3):461-70.
`Julia, et al. Tachykininergic mediation of viscerosensitive responses
`to acute inflammation in rats: role of CGRP. Am J Physiol. Jan.
`1997;272(1 Pt 1):G141-6.
`Kar, et al. Increased calcitonin gene-related peptide (CGRP), sub-
`stance P, and enkephalin immunoreactivities in dorsal spinal cord and
`loss of CGRP-immunoreactive motoneurons in arthritic rats depend
`on intact peripheral nerve supply. J Mol Neurosci. 1991;3(1):7-18.
`Katz, et al. Measurement of pain. Surg Clin North Am. Apr.
`1999;79(2):231-52.
`Kawamura, et al. Antinociceptive effect of intrathecally administered
`antiserum against calcitonin gene-related peptide on thermal and
`mechanical noxious stimuli in experimental hyperalgesic rats. Brain
`Res. Sep. 11, 1989;497(1):199-203.
`Kipriyanov. Generation of antibody molecules through antibody
`engineering. Methods Mol Biol. 2003;207:3-25.
`Kobayashi, et al. Tryptophan H33 plays an important role in
`pyrimidine (6-4) pyrimidone photoproduct binding by a high-affinity
`antibody. Protein Eng. Oct. 1999;12(10):879-84.
`Kohler, et al. Continuous cultures of fused cells secreting antibody of
`predefined specificity. Nature. Aug. 7, 1975;256(5517):495-7.
`Kumar, et al. Molecular cloning and expression ofthe Fabs of human
`autoantibodies in Escherichia coli. Determination of the heavy or
`light chain contribution to the anti-DNN-cardiolipin activity of the
`Fab. J Biol Chem. Nov. 10, 2000;275(45):35129-36.
`Kuraishi, et al. Antinociception induced in rats by intrathecal admin-
`istration of antiserum against calcitonin gene-related peptide.
`Neurosci Lett. Oct. 17, 1988;92(3):325-9.
`Lassen, et al. CGRP may play a causative role in migraine.
`Cephalalgia. Feb. 2002;22(1):54-61.
`Letter from Patentee’s representative dated Feb. 12, 2013.
`Levine, et al. Textbook of Pain. 1994, pp. 45-56.
`Little, et al. Of mice and men: hybridoma and recombinant antibod-
`ies. Immunol Today. Aug. 2000;21(8):364-70.
`Longstreth, et al. Functional bowel disorders. Gastroenterology. Apr.
`2006;130(5):1480-91.
`
`
`
`
`
`
`
`\I0.
`
`\Io.
`
`\Io.
`
`Louis, et al. Antibodies to calcitonin-gene related peptide reduce
`inflammation induced by topical mustard oil but not that due to
`carrageenin in the rat. Neurosci Lett. Jul. 31, 1989;102(2-3):257-60.
`Louis, et al. The role of substance P and calcitonin gene-related
`peptide in neurogenic plasma extravasation and vasodilatation in the
`rat. Neuroscience. 1989;32(3):581-6.
`VIacCallum, et al. Antibody-antigen interactions: contact analysis
`and binding site topography. J Mol Biol. Oct. 11, 1996;262(5):732-
`45.
`VIallee, et al. Receptor activity-modifying protein 1 determines the
`species selectivity of non-peptide CGRP receptor antagonists. J Biol
`Chem. Apr. 19, 2002;277(16):14294-8. Epub Feb. 14, 2002.
`VIarks, et al. By-passing immunization. Human antibodies from
`V—gene
`libraries displayed on phage.
`J Mol Biol. Dec.
`5,
`1991;222(3):581-97.
`VIarshall, et al. Human and rat alpha-CGRP but not calcitonin cause
`mesenteric vasodilatation in rats. Eur J Pharmacol. Apr. 16,
`1986;123(2):217-22.
`VIcCafferty, et al. Phage antibodies: filamentous phage displaying
`antibody variable domains. Nature. Dec. 6, 1990;348(6301):552-4.
`VIcCarthy, et al. Textbook of Pain. 1994, pp. 387-395.
`VIeenan, et al. The arthritis impact measurement scales. Further
`investigations of a health status measure. Arthritis Rheum. Sep.
`1982;25(9):1048-53.
`VIense, S. Pathophysiology of low back pain and the transition to the
`chronic stateiexperimental data and new concepts. Schmerz. Dec.
`2001;15(6):413-7.
`VIerck manual, Pain, 17th Ed. 1999, p. 1367, #167. (in Japanese with
`English translation).
`VIorell, et al. Metabolic properties of IgG subclasses in man. J Clin
`Invest. Apr. 1970;49(4):673-80.
`VIulderry, et al. Differential expression of alpha-CGRP and beta-
`CGRP by primary sensory neurons and enteric autonomic neurons of
`the rat. Neuroscience. Apr. 1988;25(1):195-205.
`VIullins, et al. Characterization of a calcitonin gene-related peptide
`(CGRP) receptor on mouse bone marrow cells. Regul Pept. Nov. 19,
`1993;49(1):65-72. (Abstract only).
`\Iakamura-Craig, et al. Effect of neurokinin A, substance P and
`calcitonin gene related peptide in peripheral hyperalgesia in the rat
`paw. Neurosci Lett. Mar. 11, 1991;124(1):49-51.
`\Iotice of allowance dated Apr.
`1, 2014 for L .8. Appl.
`14/086,816.
`\Iotice of allowance dated Apr. 8, 2015 for L .8. Appl.
`14/25 1,925.
`\Iotice of allowance dated Apr. 13, 2011 for US. Appl.
`12/093,638.
`\Iotice of allowance dated Jun. 19, 2012 for L .8. Appl.
`12/920,634.
`\Iotice of allowance dated Jun. 26, 2012 for L .8. Appl.
`12/920,621.
`\Iotice of allowance dated Aug. 16, 2013 for L .8. Appl.
`13/ 179,846.
`\Iotice of allowance dated Sep. 23, 2013 for L .8. Appl.
`13/870,871.
`\Iotice of allowance dated Sep. 25, 2013 for L .8. Appl.
`13/392,860.
`\Iotice of opposition dated Jul. 11, 2014 to the grant of European
`patent No. 1957106.
`\Iotice of opposition dated Jul. 16, 2014 to the grant of European
`patent No. 1957106.
`Office action dated Mar. 1, 2012 for US. Appl. No. 12/920,621.
`Office action dated Mar. 3, 2014 for US. Appl. No. 14/086,816.
`Office action dated Mar. 14, 2013 for US. Appl. No. 13/179,846.
`Office action dated Jun. 7, 2013 for US. Appl. No. 13/392,860.
`Office action dated Jun. 19, 2013 for US. Appl. No. 13/870,871.
`Office action dated Oct. 29, 2010 for US. Appl. No. 12/093,638.
`Office action dated Dec. 20, 2011 for US. Appl. No. 12/920,634.
`Olesen, et al. Calcitonin gene-related peptide receptor antagonist
`BIBN 4096 BS for the acute treatment of migraine. N Engl J Med.
`Mar. 11, 2004;350(11):1104-10.
`Olesen, et al. The Headaches. Lippincott Williams & Wilkins, Chap-
`ter 31, pp. 289-299, CGRP Involvement in Migraines. Oct. 1, 2005.
`
`\Io.
`
`\I0.
`
`\Io.
`
`\Io.
`
`\Io.
`
`4
`
`

`

`US 9,266,951 B2
`
`Page 5
`
`(56)
`
`References Cited
`OTHER PUBLICATIONS
`
`Papadopoulos, et al. Binding and neutralization of vascular
`endothelial growth factor (VEGF) and related ligands by VEGF Trap,
`ranibizumab and bevacizumab. Angiogenesis. Jun. 2012;15(2):171-
`85. doi: 10.1007/310456-011-9249-6.
`Paulus, et al. Analysis of improvement in individual rheumatoid
`arthritis patients treated with disease-modifying antirheumatic drugs,
`based on the findings in patients with placebo. The Cooperative
`Systematic Studies of Rheumatic Diseases Group. Arthritis Rheum.
`Apr. 1990;33(4):477-84.
`Peskar, et al. A monoclonal antibody to calcitonin gene-related
`peptide
`abolishes
`capsaicin-induced gastroprotection. Eur
`J
`Pharmacol. Nov. 30, 1993;250(1):201-3.
`Petersen, et al. BIBN4096BS antagonizes human alpha-calcitonin
`gene related peptide-induced headache and extracerebral artery dila-
`tation. Clin Pharmacol Ther. Mar. 2005;77(3):202-13.
`Petersen, et al. Inhibitory effect of BIBN4096BS on cephalic
`vasodilatation induced by CGRP or transcranial electrical stimula-
`tion in the rat. Br J Pharmacol. Nov. 2004; 143(6):697-704. Epub Oct.
`25, 2004.
`Plessas, et al. Migraine-like episodic pain behavior in a dog: can dogs
`suffer from migraines? JVet Intern Med. Sep.-Oct. 2013;27(5):1034-
`40. doi: 10. 1 1 1 1/jvim. 12167. Epub Aug. 26, 2013.
`Plourde, et al. Calcitonin gene-related peptide in viscerosensitive
`response to colorectal distension in rats. Am J Physiol.
`Jul.
`1997;273(1 Pt 1):G191-6.
`Plourde, et al. CGRP antagonists and capsaicin on celiac ganglia
`partly prevent postoperative gastric ileus. Peptides. Nov.-Dec.
`1993;14(6):1225-9.
`Prewett, et al. The biologic effects of C225, a chimeric monoclonal
`antibody to the EGFR, on human prostate carcinoma. J Immunother
`Emphasis Tumor Immunol. Nov. 1996;19(6):419-27.
`Ravetch, et al. Fc receptors. Annu Rev Immunol. 1991;9:457-92.
`Reinshagen, et al. Calcitonin gene-related peptide mediates the pro-
`tective effect of sensory nerves in a model of colonic injury. J
`Pharmacol Exp Ther. Aug. 1998;286(2):657-61.
`Rovero, et al. CGRP Antagonist Activity of Short C-Terminal Frag-
`ments of Human aCGRP, CGRP(23-37) and CGRP(19-37), Peptides,
`1992, 1025-1027, vol. 13.
`Rudikoff, et al. Single amino acid substitution altering antigen-bind-
`ing specificity. Proc Natl Acad Sci U S A. Mar. 1982;79(6):1979-83.
`Saleh, et al. Phase I trial of the chimeric anti-GD2 monoclonal anti-
`body ch14.18 in patients with malignant melanoma. Hum Antibodies
`Hybridomas. Jan. 1992;3(1):19-24.
`Schaible, et al. Mechanisms of pain in arthritis. Ann NY Acad Sci.
`Jun. 2002;966:343-54.
`Seong, et al. Radiation-induced alteration of pain-related signals in
`an animal model with bone invasion from cancer. Ann NYAcad Sci.
`Dec. 2004;10302179-86.
`Sheets, et al. Efficient construction of a large nonimmune phage
`antibody library: the production of high-affinity human single-chain
`antibodies to protein antigens. Proc Natl Acad Sci U S A. May 26,
`1998;95(11):6157-62.
`Smith, et al. Reversal of advanced digoxin intoxication with Fab
`fragments of digoxin-specific antibodies. N Engl J Med. Apr. 8,
`1976;294(15):797-800.
`Smith-Gill, et al. Contributions of immunoglobulin heavy and light
`chains to antibody specificity for lysozyme and two haptens. J
`Immunol. Dec. 15, 1987;139(12):4135-44.
`Song, et al. Light chains of natural antibody plays a dominant role in
`protein antigen binding. Biochem Biophys Res Comun. Feb. 16,
`2000;268(2):390-4.
`Tamura, et al. Structural correlates of an anticarcinoma antibody:
`identification of specificity-determining residues (SDRs) and devel-
`opment ofa minimally immunogenic antibody variant by retention of
`SDRs only. J Immunol. Feb. 1, 2000;164(3):1432-41.
`Tan, et al. Calcitonin gene-related peptide as an endogenous
`vasodilator: immunoblockade studies in vivo with an anti-calcitonin
`gene-related peptide monoclonal antibody and its Fab' fragment. Clin
`Sci (Lond). Dec. 1995 ;89(6): 565 -73.
`
`Tan, et al. Demonstration of the neurotransmitter role of calcitonin
`gene-related peptides (CGRP) by immunoblockage with anti-CGRP
`monoclonal antibodies. Br J Pharmacol. Mar. 1994;111(3):703-10.
`Tfelt-Hansen P., “Site of effect of LY2951742 for migraine prophy-
`laxis. Www.thelancet.com/neueology. vol. 14, Jan. 2015; 31-32.”
`Tvedskov, et al. No increase of calcitonin gene-related peptide in
`jugular blood during migraine. Ann Neurol. Oct. 2005;58(4):561-8.
`Tzabazis, et al. Antihyperalgesic effect of a recombinant herpes virus
`encoding antisense for calcitonin gene-related peptide. Anesthesiol-
`ogy. Jun. 2007;106(6):1196-203.
`U.S.App1.No. 13/870,871, filed Apr. 25, 2013.
`U.S.App1.No. 13/892,121, filed May 10, 2013.
`U.S.App1.No. 13/892,130, filed May 10, 2013.
`U.S.App1.No. 14/057,747, filed Oct. 18, 2013.
`U.S.App1.No. 14/086,816, filed Nov. 21, 2013.
`U.S.App1.No. 14/251,925, filed Apr. 14, 2014.
`U.S.App1.No. 14/295,583, filed Jun. 4, 2014.
`Vajdos, et al. Comprehensive functional maps ofthe antigen-binding
`site of an anti-ErbB2 antibody obtained with shotgun scanning
`mutagenesis. J Mol Biol. Jul. 5, 2002;320(2):415-28.
`Vater, et al. Short bioactive Spiegelmers to migraine-associated
`calcitonin gene-related peptide rapidly identified by a novel
`approach:
`tailored-SELEX. Nucleic Acids Res. Nov.
`1,
`2003;31(21):e130.
`Vaughan, et al. Human antibodies with sub-nanomolar affinities iso-
`lated from a large non-immunized phage display library. Nat
`Biotechnol. Mar. 1996;14(3):309-14.
`Wacnik, et al. Tumor-induced mechanical hyperalgesia involves
`CGRP receptors and altered innervation and vascularization of
`DsRed2 fluorescent hindpaw tumors. Pain. May 2005;115(1-2):95-
`106.
`Waeber, et al. Migraine as an inflammatory disorder. Neurology.
`2005; 64:S9-SlS.
`in
`Walter;
`et
`al., “Evaluation of cardiovascular parameters
`cynomolgus monkeys following IV administration of LBR-101, a
`monoclonal antibody against calcitonin gene-related peptide. mAbs,
`vol. 6, Issue 4, pp. 871-878.”
`Walter; et al., “TEV—48125: A Review of a Monoclonal CGRP Anti-
`body in Development for the Preventative Treatment of Migraine.
`Curr Pain Headache Rep (2015) 19:6.”
`single
`repertoire of
`Ward,
`et
`al. Binding activities of a
`immunoglobulin variable domains secreted from Escherichia coli.
`Nature. Oct. 12, 1989;341(6242):544-6.
`Wick, et al. Transient receptor potential vanilloid 1, calcitonin gene-
`related peptide, and substance P mediate nociception in acute
`pancreatitis. Am J Physiol Gastrointest Liver Physiol. May
`2006;290(5):G959-69. Epub Jan. 6, 2006.
`Winkler, et al. Changing the antigen binding specificity by single
`point mutations of an anti-p24 (HIV-1) antibody. J Immunol. Oct. 15,
`2000;165(8):4505-14
`Wong, et al. Monoclonal antibody to rat alpha-CGRP: production,
`characterization,
`and in vivo
`immunoneutralization activity.
`Hybridoma. Feb. 1993;12(1):93-106.
`Wong, et al. Preparation of a monoclonal antibody to rat alpha-CGRP
`for in vivo immunoneutralization ofpeptides. Ann NYAcad Sci. Jun.
`30, 1992;657:525-7.
`Wu, et al. Humanization of a murine monoclonal antibody by simul-
`taneous optimization of framework and CDR residues. J Mol Biol.
`Nov. 19, 1999;294(1):151-62.
`Xu, F.T. Study on the Mechanism of SP and CGRP in the Chronic
`Pain and Knee Joint. Master Thesis. Guangxi Medical University.
`May 2005. (In Chinese with English abstract).
`Zeller, et al. CGRP function-blocking antibodies inhibit neurogenic
`vasodilatation without affecting heart rate or arterial blood pressure
`in the rat. Br JPharmacol. Dec. 2008;155(7):1093-103. doi: 10.1038/
`bjp.2008.334. Epub Sep. 8, 2008.
`Zhang, et al. Rheumatoid factor specificity of a VH3 -encoded anti-
`body is dependent on the heavy chain CDR3 region and is indepen-
`dent of protein A binding. J Immunol. Sep. 1, 1998;161(5):2284-9.
`Office action dated Oct. 16, 2015 for US. Appl. No. 14/841,479.
`Office action dated Oct. 19, 2015 for US. Appl. No. 14/841,440.
`Office action dated Nov. 4, 2015 for US. Appl. No. 14/719,015.
`
`5
`
`

`

`US 9,266,951 B2
`Page 6
`
`(56)
`
`References Cited
`OTHER PUBLICATIONS
`
`Aiyar, et al. Pharmacology of SB-273779, a nonpeptide calcitonin
`gene-related peptide
`1
`receptor antagonist. The
`Journal of
`Pharmacolog
`and
`Experimental
`Therapeutic s.
`2001 ;
`296(3):768-775.
`Shaw, et al. The effect of monoclonal antibodies to calcitonin gene-
`related peptide (CGRP) on CGRP-induced vasodilatation in pig
`coronary artery rings. Br. J. Pharmacol. 1992; 1062196-198.
`Szabat, et al. Production and characterization of monoclonal anti-
`body against human calcitonin gene-related peptide (CGRP) and its
`immunohistochemical application to salivary glands. Histochemical
`Journal. 1994; 26:317-326.
`Bowen, et al. Tumor necrosis factor-alpha stimulation of calcitonin
`gene-related peptide expression and secretion from rat trigeminal
`ganglion neurons. J Neurochem. Jan. 2006;96(1):65-77. Epub Nov.
`8, 2005.
`
`the CGRP receptor antagonist
`al. Effect of
`et
`EdVinsson,
`BIBN4096BS in human cerebral, coronary and omental arteries and
`in SK-N-MC cells. Eur J Pharmacol. Jan. 2, 2002;434(1-2):49-53.
`Fanciullacci, et al. Increase in plasma calcitonin gene-related peptide
`from the extracerebral circulation during nitroglycerin-induced clus-
`ter headache attack. Pain. Feb. 1995;60(2):119-23.
`Poyner, et al. Structural determinants for binding to CGRP receptors
`expressed by human SK-N-MC and Col 29 cells: studies with chi-
`meric and other peptides. Br J Pharmacol. Aug. 1998;124(8):1659-
`66.
`Takhshid, et al. Characterization and effects on CAMP accumulation
`of adrenomedullin and calcitonin gene-related peptide (CGRP)
`receptors in dissociated rat spinal cord cell culture. Br J Pharmacol.
`Jun. 2006;148(4):459-68. Epub May 15, 2006.
`Notice of allowance dated Jan. 7, 2016 for US. Appl. No.
`14/841,440.
`Notice of allowance dated Dec. 23, 2015 for US. Appl. No.
`14/841,479.
`
`6
`
`

`

`U.S. Patent
`
`eF
`
`US 9,266,951 B2
`
`Eat—EV9M44%4mm4N94H243H4%4NN>45%Mcan;
`
`
`
`
`
` .3.Em.._........4....33M.z,,.am,oz“:4m.EEJIEE?o.Hc.H3,45mm4mQ,
`.NM,S....,.,.326N4«5E:H.
`
`
`
`«a95mg
`
`
`
`
`
`
`
`._..2N...1a;.g,.,2N...6#4.:.,.......hehema;,.
`
`
`
`
`
`
`
`
`
`
`
`
`
`,.Ew...
`
`a...w...24c
`m:4?EHNNN
`
`NE?oNiON
`
`
`
`3.4meNfiNm
`
`343N33
`
`$44.3$3
`
`43484E
`
`32243
`
`
`
`3.46va4:43.
`
`3.33.6$3
`333%242
`464:$2
`N643SHE
`5.3Eva
`4.4N23EaNE
`
`SEQ:25Q
`
`93Q
`
`nah
`
`n8
`
`EN
`
`2%
`
`4.4m
`
`mm
`
`E:
`
`38
`
`Ea
`
`9E
`
`35
`
`w<3
`
`SE.
`
`2.3
`
`8%
`
`3m:
`
`N02”
`
`3:
`
`mma
`
`mnG
`
`mm:
`
`7
`
`
`

`

`US. Patent
`
`Feb. 23, 2016
`
`Sheet 2 of 16
`
`US 9,266,951 B2
`
`Figure 2A
`
`AUG
`
`COMFO'
`
`CGRP 8-37
`400nmollkg
`
`4901
`25mg/kg IP
`72h pre-stim
`
`8
`
`

`

`US. Patent
`
`Feb. 23, 2016
`
`Sheet 3 of 16
`
`US 9,266,951 B2
`
`Figure 28
`
`12000
`
`11000
`
`10000
`
`AUC
`
`9000
`
`8000
`
`7000
`
`6000
`
`5000
`
`4000
`
`3000
`
`2000
`
`1000
`
`No Ab
`
`7D11
`
`4901
`
`25mglkg IP 25mglkg lP
`
`9
`
`

`

`US. Patent
`
`Feb. 23, 2016
`
`Sheet 4 0f 16
`
`US 9,266,951 B2
`
`Figure 3
`
`60000
`
`50000
`
`40000
`
`c:
`2 30000
`
`20000
`
`10000
`
`25mglkg
`
`5mglkg
`
`2.5mglkg
`
`1mglkg
`
`controls
`
`10
`
`10
`
`

`

`US. Patent
`
`Feb. 23, 2016
`
`Sheet 5 of 16
`
`US 9,266,951 B2
`
`Figure 4A
`
`I 4901 10 mg/kg IV
`
`El 4901 lmg/kg IV
`D Control 10 mg/kg IV
`
`175
`
`1 50
`
`
`
`0
`
`*3’:
`
`*1?
`
`
`l H ‘
`
`*5?
`
`,
`
`**
`
`7’:
`
`E7»
`
`
`
`30
`
`60
`
`90
`
`12
`
`0
`
`Time post injection (min)
`
`11
`
`11
`
`

`

`US. Patent
`
`Feb. 23, 2016
`
`Sheet 6 of 16
`
`US 9,266,951 B2
`
`Figure 4B
`
`-7E9
`
`-8E36
`
`__
`
`72*
`
`
`
`0
`
`30
`
`60
`
`90
`
`120
`
`Time post
`injection (min)
`
`12
`
`100
`
`75
`
`50
`
`25
`
`w
`
`E g
`
`a:
`n.
`
`12
`
`

`

`US. Patent
`
`Feb. 23, 2016
`
`Sheet 7 of 16
`
`US 9,266,951 B2
`
`Figure 5
`
`Bold=Kabat CDR
`Underline=Chothia CDR
`
`G1